Key result
Combination therapy with immunosuppressants and targeted pulmonary pressure-reducing drugs decreased systolic pulmonary arterial pressure to 40 mmHg and reduced NT-proBNP levels to 62.3 pg/ml.
Why the study?
Chronic active EBV infection can cause cardiovascular complications, but no prior reports highlight cases in conjunction with systemic vasculitis and pulmonary hypertension.
Does combination therapy with immunosuppressants and pulmonary vasodilators improve pulmonary pressures in a pediatric patient with CAEBV-associated PAH and systemic vasculitis?
Case Report (n=1)
No
Does combination therapy with immunosuppressants and pulmonary vasodilators improve pulmonary pressures in a pediatric patient with CAEBV-associated PAH and systemic vasculitis?
This case highlights that chronic active Epstein-Barr virus infection should be considered in the differential diagnosis of pediatric patients presenting with secondary pulmonary arterial hypertension and systemic vasculitis.
Authors
No takes yet. Share an insight, caveat, or question.
May warrant cardiovascular screening in pediatric CAEBV; leaves open the association's prevalence and causality.
Ba et al. (2019) conducted a case report in Chronic Active Epstein-Barr Virus Infection with Systemic Vasculitis and Pulmonary Arterial Hypertension (n=1). Immunosuppressants and targeted pulmonary pressure-reducing drugs was evaluated on Systolic pulmonary arterial pressure and NT-proBNP levels. Combination therapy with immunosuppressants and targeted pulmonary pressure-reducing drugs decreased systolic pulmonary arterial pressure to 40 mmHg and reduced NT-proBNP levels to 62.3 pg/ml.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: